Jazz Pharmaceuticals PLC - (JAZZ) closed at $234.76 on November 6, 2026, up 3.3% from the previous close, on volume of 775,526 shares (30-day average 839,689).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Put Spread | 20-Nov-26180 : 200 P | 4,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Jazz Advances Early JZP269 Study as Investors Await Safety Data
TipRanks (Wed, 4-Nov 11:31 AM ET)
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
PRNewswire (Tue, 3-Nov 4:15 PM ET)
Jazz climbs as 2026 revenue guidance boosted
Seeking Alpha News (Tue, 3-Nov 11:35 AM ET)
Jazz’s Epidyolex Follow-Up Study Reaches Completion: What It Means for JAZZ Investors
TipRanks (Tue, 3-Nov 11:30 AM ET)
TipRanks (Tue, 3-Nov 8:40 AM ET)
TD Cowen Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanks (Tue, 3-Nov 8:37 AM ET)
TipRanks (Tue, 3-Nov 8:30 AM ET)
Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanks (Tue, 3-Nov 7:56 AM ET)
Canaccord Genuity Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanks (Tue, 3-Nov 7:54 AM ET)
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Alcon (ALC)
TipRanks (Tue, 3-Nov 5:40 AM ET)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals PLC - trades on the NASDAQ stock market under the symbol JAZZ.
As of November 6, 2026, JAZZ stock price climbed to $234.76 with 775,526 million shares trading.
JAZZ has a beta of -0.13, meaning it tends to be less sensitive to market movements. JAZZ has a correlation of 0.00 to the broad based SPY ETF.
JAZZ has a market cap of $14.73 billion. This is considered a Large Cap stock.
Last quarter Jazz Pharmaceuticals PLC - reported $1 billion in Revenue and -$3.88 earnings per share. This beat revenue expectation by $31 million and missed earnings estimates by -$1.08.
In the last 3 years, JAZZ traded as high as $266.38 and as low as $95.49.
The top ETF exchange traded funds that JAZZ belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
JAZZ has outperformed the market in the last year with a price return of +75.1% while the SPY ETF gained +10.8%. However, in the short term, JAZZ had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.5% vs -4.1% return in SPY. But in the last 2 weeks, JAZZ shares have fared better than the market returning +9.7% compared to SPY -3.2%.
JAZZ support price is $222.54 and resistance is $232.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAZZ shares will trade within this expected range on the day.
